Form 8-K - Current report:
SEC Accession No. 0001641172-25-015338
Filing Date
2025-06-17
Accepted
2025-06-17 07:33:46
Documents
19
Period of Report
2025-06-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 43101
2 EX-3.1 ex3-1.htm EX-3.1 5488
3 EX-3.2 ex3-2.htm EX-3.2 149295
4 EX-99.1 ex99-1.htm EX-99.1 32526
5 EX-99.2 ex99-2.htm EX-99.2 26184
6 GRAPHIC ex99-1_001.jpg GRAPHIC 11137
7 GRAPHIC ex99-2_001.jpg GRAPHIC 11137
8 GRAPHIC ex99-2_002.jpg GRAPHIC 2938
  Complete submission text file 0001641172-25-015338.txt   507170

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE ocx-20250613.xsd EX-101.SCH 3011
10 XBRL LABEL FILE ocx-20250613_lab.xml EX-101.LAB 34239
11 XBRL PRESENTATION FILE ocx-20250613_pre.xml EX-101.PRE 22357
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3786
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 251051831
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)